Request Demo
Last update 15 Jul 2026
GR-1901
Last update 15 Jul 2026
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms GR 1901, GR-1901, GR1901 |
Target |
Action inhibitors, stimulants |
Mechanism CD123 inhibitors(Interleukin-3 receptor subunit alpha inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with GR-1901CTR20222311
GR1901注射液在复发/难治急性髓系白血病患者中多次给药的安全性、药代动力学、免疫原性和初步疗效的I期临床研究
[Translation] Phase I clinical study on the safety, pharmacokinetics, immunogenicity and preliminary efficacy of GR1901 injection after multiple administration in patients with relapsed/refractory acute myeloid leukemia
100 Clinical Results associated with GR-1901
Login to view more data
100 Translational Medicine associated with GR-1901
Login to view more data
100 Patents (Medical) associated with GR-1901
Login to view more data
100 Deals associated with GR-1901
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Myeloid Leukemia with Myelodysplasia-Related Changes | Phase 1 | China | 10 Nov 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free